BR112022009602A2 - Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos - Google Patents
Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmosInfo
- Publication number
- BR112022009602A2 BR112022009602A2 BR112022009602A BR112022009602A BR112022009602A2 BR 112022009602 A2 BR112022009602 A2 BR 112022009602A2 BR 112022009602 A BR112022009602 A BR 112022009602A BR 112022009602 A BR112022009602 A BR 112022009602A BR 112022009602 A2 BR112022009602 A2 BR 112022009602A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- chctric
- ch38c
- antibodies
- car
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
ANTICORPOS ANTI-CD79 CH38C-CD79 CHCTRIC, CÉLULAS CAR-T, e USOS DOS MESMOS. A presente descrição refere-se a receptores de antígenos quiméricos (Carros) que visam especificamente um Agrupamento de proteína 79b de Diferenciação (CD79b), e células imunoresponsivas compreendendo tais carros, para o tratamento de câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962936662P | 2019-11-18 | 2019-11-18 | |
PCT/IB2020/060826 WO2021099944A1 (en) | 2019-11-18 | 2020-11-17 | Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009602A2 true BR112022009602A2 (pt) | 2022-09-20 |
Family
ID=73598921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009602A BR112022009602A2 (pt) | 2019-11-18 | 2020-11-17 | Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20210145878A1 (pt) |
EP (1) | EP4061837A1 (pt) |
JP (1) | JP2023502652A (pt) |
KR (1) | KR20220114560A (pt) |
CN (1) | CN114945590A (pt) |
AU (1) | AU2020387709A1 (pt) |
BR (1) | BR112022009602A2 (pt) |
CA (1) | CA3161825A1 (pt) |
CL (1) | CL2022001299A1 (pt) |
CO (1) | CO2022008484A2 (pt) |
CR (1) | CR20220221A (pt) |
DO (1) | DOP2022000102A (pt) |
EC (1) | ECSP22048631A (pt) |
IL (1) | IL293046A (pt) |
JO (1) | JOP20220117A1 (pt) |
MX (1) | MX2022005983A (pt) |
PE (1) | PE20221273A1 (pt) |
WO (1) | WO2021099944A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
JP2024512035A (ja) * | 2021-03-24 | 2024-03-18 | ヤンセン バイオテツク,インコーポレーテツド | Cd22及びcd79bを標的とする抗体 |
EP4347650A1 (en) * | 2021-06-01 | 2024-04-10 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-cd79b antibodies |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
EP1539235A2 (en) * | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
WO2004111233A1 (ja) | 2003-06-11 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
US7566772B2 (en) * | 2005-01-26 | 2009-07-28 | Amgen Fremont Inc. | Antibodies against interleukin-1β |
EP1870459B1 (en) | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
US9212230B2 (en) | 2007-03-29 | 2015-12-15 | Genmab A/S | Bispecific antibodies and methods for production thereof |
CN102112492B (zh) * | 2007-11-14 | 2015-02-25 | 中外制药株式会社 | 使用抗gpr49抗体的癌症的诊断和治疗 |
AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US8476008B2 (en) * | 2008-07-23 | 2013-07-02 | Diabetomics, Llc | Methods for detecting pre-diabetes and diabetes |
WO2010019656A1 (en) * | 2008-08-12 | 2010-02-18 | Wyeth | Humanized anti-rage antibody |
WO2010059543A1 (en) * | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
AU2010315101B2 (en) * | 2009-11-04 | 2016-01-28 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
US10654926B2 (en) * | 2014-05-02 | 2020-05-19 | Medimmune Limited | P2X4 antibodies and uses thereof |
SI3280729T1 (sl) * | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
EP3349794A4 (en) * | 2015-09-16 | 2019-07-31 | Ablexis, LLC | ANTI-CD115 ANTIBODIES |
JP2018535655A (ja) * | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | Asgr阻害剤 |
CN115073581A (zh) * | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
EP3635099A4 (en) * | 2017-06-07 | 2021-02-24 | The General Hospital Corporation | T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR |
EP3684816A1 (en) | 2017-09-22 | 2020-07-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
WO2019092452A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
EP3755718A1 (en) * | 2018-02-21 | 2020-12-30 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
EP3794034A1 (en) * | 2018-05-15 | 2021-03-24 | Autolus Limited | Chimeric antigen receptor |
GB201807870D0 (en) * | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
US20220226374A1 (en) * | 2018-06-14 | 2022-07-21 | 2seventy bio, Inc | Cd79b chimeric antigen receptors |
CN109265565B (zh) * | 2018-10-10 | 2021-06-01 | 苏州大学 | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 |
WO2020124021A1 (en) * | 2018-12-13 | 2020-06-18 | The General Hospital Corporation | Chimeric antigen receptors targeting cd79b and cd19 |
-
2020
- 2020-11-17 MX MX2022005983A patent/MX2022005983A/es unknown
- 2020-11-17 US US16/950,296 patent/US20210145878A1/en active Pending
- 2020-11-17 KR KR1020227020586A patent/KR20220114560A/ko active Search and Examination
- 2020-11-17 WO PCT/IB2020/060826 patent/WO2021099944A1/en active Application Filing
- 2020-11-17 JP JP2022528628A patent/JP2023502652A/ja active Pending
- 2020-11-17 BR BR112022009602A patent/BR112022009602A2/pt unknown
- 2020-11-17 CA CA3161825A patent/CA3161825A1/en active Pending
- 2020-11-17 CN CN202080093567.1A patent/CN114945590A/zh active Pending
- 2020-11-17 EP EP20815943.4A patent/EP4061837A1/en active Pending
- 2020-11-17 AU AU2020387709A patent/AU2020387709A1/en active Pending
- 2020-11-17 JO JOP/2022/0117A patent/JOP20220117A1/ar unknown
- 2020-11-17 CR CR20220221A patent/CR20220221A/es unknown
- 2020-11-17 PE PE2022000809A patent/PE20221273A1/es unknown
- 2020-11-17 IL IL293046A patent/IL293046A/en unknown
-
2022
- 2022-05-17 CL CL2022001299A patent/CL2022001299A1/es unknown
- 2022-05-18 DO DO2022000102A patent/DOP2022000102A/es unknown
- 2022-06-16 CO CONC2022/0008484A patent/CO2022008484A2/es unknown
- 2022-06-17 EC ECSENADI202248631A patent/ECSP22048631A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4061837A1 (en) | 2022-09-28 |
CA3161825A1 (en) | 2021-05-27 |
CL2022001299A1 (es) | 2023-03-03 |
JP2023502652A (ja) | 2023-01-25 |
DOP2022000102A (es) | 2022-09-30 |
PE20221273A1 (es) | 2022-09-01 |
KR20220114560A (ko) | 2022-08-17 |
ECSP22048631A (es) | 2022-07-29 |
CO2022008484A2 (es) | 2022-06-30 |
AU2020387709A1 (en) | 2022-07-07 |
CN114945590A (zh) | 2022-08-26 |
WO2021099944A1 (en) | 2021-05-27 |
MX2022005983A (es) | 2022-09-07 |
IL293046A (en) | 2022-07-01 |
US20210145878A1 (en) | 2021-05-20 |
CR20220221A (es) | 2022-07-11 |
JOP20220117A1 (ar) | 2023-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022009602A2 (pt) | Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos | |
BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
BR112021013824A2 (pt) | Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos | |
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
AR104809A1 (es) | Anticuerpos anti-cd40 y usos de los mismos | |
BR112017003582A2 (pt) | anticorpos, composições e usos | |
BR112012021327A2 (pt) | anticorpo monoclonal anti-her2 completamente humano, método de preparação e uso do mesmo. | |
PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
MY189159A (en) | Multispecific antigen-binding molecules and uses thereof | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
BR112018010385A2 (pt) | anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer. | |
BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
EA201991845A1 (ru) | Фармацевтические комбинации, содержащие антитело к ly75 |